Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (247)
  3. Review (13)
  4. Guidelines (11)
  5. Research Letter (9)
  6. Book Section (6)
  7. Correspondence (4)
  8. Editorial (4)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (669)
  2. Department of Medicine (669)
  3. Hematologic Malignancies, Division of (669)
  4. Lymphoma (669)
  5. Population Sciences Research Program (669)
  6. Survivorship Research (171)

More Groups

People
  1. Alison Moskowitz (234)
  2. Andrew Zelenetz (168)
  3. Paul Hamlin (139)
  4. Ariela Noy (138)
  5. David Straus (122)
  6. Maria Palomba (111)

More People

Years
  1. 2025 (16)
  2. 2024 (51)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Leukemia and Lymphoma (19)
  5. Annals of Oncology (18)
  6. Blood Advances (18)

More Publications

Publishers
  1. American Society of Hematology (276)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (34)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (23)

More Publishers

Results (669)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Subsequent treatment and clinical outcome following induction therapy on a phase II study of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Ruan, J.; Orlando, E. H.; Moskowitz, A.; Chen, Z.; Mehta-Shah, N.; Sokol, L.; Horwitz, S.; Rutherford, S. C.; Sahni, T.; Melnick, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed/refractory cytotoxic lymphomas: Dose escalation and optimization
    Meeting Abstract

    Zain, J.; Iyer, S. P.; Marchi, E.; Gandhi, M.; Kim, Y. H.; Khodadoust, M. S.; Brammer, J. E.; Poh, C.; Porcu, P.; Dilley, K.; more...
    Blood (2024)

    Fulltext@MSK | Save